Literature DB >> 22320262

Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma.

Zhi-Hui Yang1, Qiong Dai, Ying-Jiang Gu, Qing-Xi Guo, Li Gong.   

Abstract

Toll-like receptors (TLR) play a pivotal role in sensing a wide range of pathogens, including bacteria, fungi and viruses. A dysregulation of TLR signaling may increase the risk of developing chronic inflammatory diseases and cancers. The aim of this study was to investigate the association of TLR2 R753Q, TLR4 D299G, and T399I polymorphisms with nasopharyngeal carcinoma (NPC) and to explore the effects of these polymorphisms on cytokine and chemokine expression in NPC biopsies. The genotypes of the three loci among 236 patients with NPC and 287 healthy controls were determined by PCR-RFLP. Cytokines and chemokines mRNA and protein in NPC biopsies were measured by real-time quantitative PCR and ELISA, respectively. Results showed that the combined CT/TT genotype of T399I was associated with increased NPC risk, with an odds ratio of 1.853 (95% confidence interval: 1.184-2.961). Also, individuals with the T allele of T399I showed a 1.842-fold increase in NPC risk compared to those with the T399I C allele (95% confidence interval: 1.213-3.015). Messenger RNA levels of interleukin (IL)-1α, tumor necrosis factor-α and IL-10 were significantly elevated in patients with T399I combined CT/TT genotype; IL-1α and IL-10 protein concentration significantly increased in NPC patients with T399I combined CT/TT genotype compared to those with the T399I CC genotype. Our data suggest that TLR4 T399I modify cytokines and chemokines patterns and play a role in the development of NPC.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22320262     DOI: 10.1111/j.1349-7006.2012.02210.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  15 in total

Review 1.  TLR4 Polymorphisms and Expression in Solid Cancers.

Authors:  Nilesh Pandey; Alex Chauhan; Neeraj Jain
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

2.  Toll-like receptor-9 in hypoxic nasopharyngeal carcinoma cells and its correlation with cell proliferation and apoptosis.

Authors:  Feng Zhang; Deli Wang; Fasheng Chen
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

Review 3.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607

Review 4.  Potential association between TLR4 and chitinase 3-like 1 (CHI3L1/YKL-40) signaling on colonic epithelial cells in inflammatory bowel disease and colitis-associated cancer.

Authors:  A Kamba; I-A Lee; E Mizoguchi
Journal:  Curr Mol Med       Date:  2013-08       Impact factor: 2.222

5.  Subregional Radiomics Analysis of PET/CT Imaging with Intratumor Partitioning: Application to Prognosis for Nasopharyngeal Carcinoma.

Authors:  Hui Xu; Wenbing Lv; Hui Feng; Dongyang Du; Qingyu Yuan; Quanshi Wang; Zhenhui Dai; Wei Yang; Qianjin Feng; Jianhua Ma; Lijun Lu
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

6.  Association of TLR5 gene polymorphisms in ulcerative colitis patients of north India and their role in cytokine homeostasis.

Authors:  Naresh Kumar Meena; Vineet Ahuja; Kusumlata Meena; Jaishree Paul
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 7.  Trial Watch: Toll-like receptor agonists for cancer therapy.

Authors:  Erika Vacchelli; Alexander Eggermont; Catherine Sautès-Fridman; Jérôme Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110

8.  Association of TLR2 and TLR4 polymorphisms with risk of cancer: a meta-analysis.

Authors:  Longbiao Zhu; Hua Yuan; Tao Jiang; Ruixia Wang; Hongxia Ma; Shuangyue Zhang
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

9.  Trial Watch: Toll-like receptor agonists in oncological indications.

Authors:  Fernando Aranda; Erika Vacchelli; Florine Obrist; Alexander Eggermont; Jérôme Galon; Catherine Sautès-Fridman; Isabelle Cremer; Jan Henrik Ter Meulen; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-08-01       Impact factor: 8.110

Review 10.  Toll-like receptors and cancer, particularly oral squamous cell carcinoma.

Authors:  Alison Mary Rich; Haizal Mohd Hussaini; Venkata P B Parachuru; Gregory J Seymour
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.